Announcing the first novel class of rapid-onset antidepressants in clinical practice
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
This study was designed with the rational aim/purpose of announcing and discussing the new class of rapid-onset antidepressants that will bring forth significant improvement and positive impact to the management of patients with depression disorders in clinical practice. The class of N-methyl-D-aspartate-glutamatergic ionoceptor blockers represent the first separate novel class of rapid-onset antidepressants with a direct action on the excitatory glutamatergic neurotransmission system but no direct action on the serotonergic, noradrenergic, or dopaminergic neurotransmission systems. It consistently fits into the antidepressants' classification nomenclature, and the pharmacological properties also deemed it appropriate to be accepted and announced as the first separate novel class of rapid-onset antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Developed for adjunctive use for TRD, apimostinel acts as a functional antagonist at the glycine B site of NMDA receptors [165].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
In the citing paper
“Apimostinel (NRX-1074/AGN-241751) is a higher-potency rapastinel analog with increased bioavailability.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
In the citing paper
“Apimostinel has been tested in two phase I studies and a larger phase II RDBPCT, showing rapid AD effects after a single, high-dose IV administration [165].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
Citations
Cites
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,336
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku340 · Cited by 4,632
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Cited by
Encore: Behavioural animal models of stress, depression and mood disorders
Petković, A., & Chaudhury, D. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.931964 · Cited by 85
“In previous decades, there has not been much progress in the discovery of completely novel non-monoaminergic antidepressants, with exception of NMDA-receptor blockers, such as ketamine (Zanos and Gould, 2018; Fasipe, 2019; Fasipe et al., 2019).”
BackgroundPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Apimostinel has been tested in two phase I studies and a larger phase II RDBPCT, showing rapid AD effects after a single, high-dose IV administration [165].”
BackgroundGlutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
Fasipe, O. J., Agede, O. A., & Enikuomehin, A. C. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0108 · Cited by 18
Self-citationShnayder, N. A., Kidyaeva, A. V., Vaiman, E. E., Asadullin, A. R., Петрова, М. М., Kaskaeva, D. S., Matyushin, G. V., Evsyukov, A. A., Galko, E. V., Garganeeva, N. P., et al. (2023) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2023-3-2-72-119 · Cited by 12
“This class of ADs includes bupropion [62, 63].”
BackgroundInfluential
Metadata
- Authors
- Fasipe, O., Akhideno, P., Owhin, O., & Ibiyemi-Fasipe, O.
- Affiliations
- Irrua Specialist Teaching Hospital (NG)
- Venue
- Journal of Medical Sciences
- Published
- 2019
- Volume
- 39
- Issue
- 5
- Pages
- 205
- ISSN
- 1011-4564 (ISSN-L)
- OpenAlex
- W2978832855
- Cited by
- 6
- References
- 59
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Medical Sciences (publishedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- rapid-acting antidepressants, NMDA receptor antagonists, glutamatergic neurotransmission, depression, antidepressant classification, clinical practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Announcing the first novel class of rapid-onset antidepressants in clinical practice. https://app.cochat.ai/papers/10.4103/jmedsci.jmedsci_36_19
- The paper
- Fasipe, O., Akhideno, P., Owhin, O., & Ibiyemi-Fasipe, O. (2019). Announcing the first novel class of rapid-onset antidepressants in clinical practice. Journal of Medical Sciences. https://doi.org/10.4103/jmedsci.jmedsci_36_19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.